|Budget Amount *help
¥75,700,000 (Direct Cost: ¥75,700,000)
Fiscal Year 2009: ¥13,200,000 (Direct Cost: ¥13,200,000)
Fiscal Year 2008: ¥13,200,000 (Direct Cost: ¥13,200,000)
Fiscal Year 2007: ¥16,500,000 (Direct Cost: ¥16,500,000)
Fiscal Year 2006: ¥16,500,000 (Direct Cost: ¥16,500,000)
Fiscal Year 2005: ¥16,300,000 (Direct Cost: ¥16,300,000)
In the present study, we conducted a chemopreventive trial on colorectal cancer, using ACF, precursors of polyps, as surrogate lesions, and results clearly indicate that administration of sulindac for 2 months gave rise to almost equal effectiveness as those of previously reported trials in which sulindac was administered for years. We also performed animal experiment using mouse colon carcinogenesis model to examine the effect of inhibitor to GST-π which was highly expressed in ACF, and found a dramatic prevention effect on colon cancer development. Thus an approach to target GST-π in ACF is a promising modality for chemoprevention of colorectal cancer.